Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals CEO discusses progress with across clinical programs. https://lnkd.in/eEFaAafC

Hemogenyx Pharmaceuticals outlines significant progress with HEMO-CAR-T in 2023 https://lnkd.in/dPMRFCw6

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) chair Marc Feldmann, in the company’s final results statement, described the year as a “period was a vital one in the progression of the company.” During the year the junior #biopharmaceutical group, which is developing new therapies and treatments for blood #diseases, raised capital on a number of occasions to support this progress. More at #Proactive #ProactiveInvestors http://ow.ly/2mJ8105qMU6

In a recent article, I said at least 20 micro-cap life sciences stocks were waiting to pop once interest returned to the sector. Investors can now add Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) to the watch list after it pulled off the near impossible by raising $4.2 million at a time when investors have largely gone into hibernation. More at #Proactive #ProactiveInvestors http://ow.ly/xrHs105oWvH #LSE #OTC #HEMO #HOPHF

Hemogenyx Pharmaceuticals (LSE:HEMO) CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones. Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. #LSE #HEMO Watch at #Proactive #ProactiveInvestors https://lnkd.in/eDSFn_4M

ICYMI: Hemogenyx Pharmaceuticals now has a green light to go forward with its plans for a phase 1 clinical trial for HEMO-CAR-T. #leusm #AcuteMyeloidLeukemia Read more: https://lnkd.in/emgn9GE2

 Hemogenyx Pharmaceuticals has received a green light from the US Food and Drug Administration (FDA) to proceed with a Phase I clinical trial for its chimeric antigen receptor (CAR) T-therapy, designed to combat acute myeloid leukaemia (AML) in the United States.   https://lnkd.in/dTuXQJey #fdaapproval #unitedstates #america #healthcarenews #trendingnews #medicalnews #worldnews

DelveInsight Business Research LLP, a leading market research and consulting firm, provides comprehensive insights into the aplastic anemia market. Their analysis encompasses various factors influencing market growth, including epidemiology, treatment landscape, pipeline therapies, and key market players. Some of the Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Inc., Gamida Cell Ltd. Elixirgen Therapeutics, Inc., Hangzhou Zede Pharmaceutical Technology, Cellenkos, Inc., Hemogenyx Pharmaceuticals, and others. The Aplastic Anemia Market presents both challenges and opportunities for stakeholders across the healthcare continuum. DelveInsight's comprehensive insights empower stakeholders to navigate this complex landscape effectively. #market #marketsize #marketshare #marketforecast #marketanalysis #marketgrowth #marketdynamics

Roast News Service - RNS - 9th February 2024                           #BZT #PREM #BEN #OCTP #PAT #HEMO #RENX Bezant Resources PlcPremier African MineralsBens Creek Group PLcOxford Cannabinoid Technologies Holdings PlcPanthera Resources PLCHemogenyx PharmaceuticalsRenalytix